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Background
Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder character-
ized by progressive accumulation of monomorphic B-cells in peripheral blood, bone marrow, 
spleen, and lymph nodes.
CLL represents the most common form of leukemia of adults in Western countries [1]. The 
Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Insti-
tute (NCI) reports an incidence of 4.9 new cases per 100,000 men and women per year [2]. 
CCL is most frequently diagnosed among people aged 65-74 with a median age at diagnosis 
of 70 years (about two third ≥65 years) and this malignancy is more common among men 
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aBstract
BACKGROUND: In the last years genomic and somatic alterations have shown to play a pivotal role in the pathogenesis 
of chronic lymphocytic leukemia (CLL) and new prognostic factors have been identified accordingly.
AIM: To describe a real-life diagnostic and therapeutic approach to CLL that takes into account the role of genomic and 
somatic prognostic factors in the risk stratification of developing progressive disease, and treatment decision.
METHODS: This new proposal has been developed and validated by ten key opinion leaders from Tuscany Region during 
two Expert Meetings. The approach suggested comes from their experience in daily clinical practice and is supported by 
guidelines recommendations, clinical trials results, and drugs prescribing conditions in Italy.
RESULTS: Beside TP53 deletion or mutated status, the Expert Panel highlighted the importance of the IGHV mutation 
status characterization, since the diagnosis, in order to identify patients who will have a more aggressive progression. 
Furthermore, just before starting treatment, to obtain useful prognostic information and indication in the selection of the 
therapy, they recommend cytogenetic analysis for the detection of del(11q), trisomy 12, del(13q), del(17p), conventional 
karyotyping of stimulated CLL cells, TP53 sequencing, and molecular genetic analysis to detect IGHV mutation status.
CONCLUSIONS: The Expert Panel recognized the limitations associated with traditional staging systems in identifying 
patients who will have a more aggressive disease course and predicting response to treatment and suggested a real-life 
diagnostic and therapeutic approach to CLL to update the current patient management in light of recent advances that have 
improved understanding of CLL. 
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than women (6.8 vs 3.5 per 100,000 persons, 
respectively) [2].
The clinical course of the disease is ex-
tremely variable: while the majority of CLL 
patients is asymptomatic at diagnosis and be-
comes symptomatic within a few years, a part 
of patients remains asymptomatic for decades 
with a percentage of 20-30% who presents a 
life expectancy equal to that of the general 
population [3]. Due to this heterogeneity, it is 
very important to identify, since the diagno-
sis, which patients will have a more aggres-
sive progression.
The oldest, and still most used, staging 
systems in CLL are Rai [4,5] and Binet [6] 
classifications. Both of them define three 
prognostic groups with different disease bur-
den (Table I) and are only based on physical 
examination (lymph node involvement, hep-
atomegaly, and/or splenomegaly) and blood 
test results (presence of anemia or thrombo-
cytopenia).
Despite their widespread use, these clas-
sifications have shown some limitations in 
identifying patients who will have a more 
aggressive disease course and predicting re-
sponse to treatment [7].
Recently, genomic and somatic altera-
tions have shown to play a pivotal role in the 
pathogenesis of CLL and new prognostic fac-
tors have been identified accordingly.
In particular, studies on the variable re-
gion of the immunoglobulin heavy chain gene 
(IGHV) have shown that the unmutated gene 
is associated with a worse prognosis and a 
significant reduction of survival compared to 
patients with mutated pattern [8,9]. Also, the 
advances on cytogenetic alterations allowed 
to identify patients with favorable [del(13q)] 
and unfavorable [del(11q), del(17p)] progno-
sis [10,11]. The presence of del(17p), which 
reflects the loss of TP53 gene, is frequently associated with the mutation of the remaining 
TP53 allele and worse outcomes and shorter survival [10,11]. Furthermore, the mutation of 
TP53 is associated with a reduction of overall and progression free survival (PFS), even in the 
absence of del(17p) [10,11].
From these findings, new prognostic scores have been developed in order to overcome the 
limitations of the classical staging systems.
The international prognostic index for patients with chronic lymphocytic leukemia (CLL-
IPI) [12] used data from 3472 patients and identified five independent prognostic factors im-
pacting 5-year overall survival (OS): deleted or mutated TP53 status, unmutated IGHV, serum 
β2-microglobulin >3.5 mg/L, Binet stage B/C or Rai I-IV, and age >65 years. Furthermore, the 
results of the univariate analyses showed the impact of each factor on CLL 10-year prognosis 
(Table II).
The Barcelona score [13] aimed at simplifying the CLL-IPI developing a biomarkers-only 
prognostic system based on the two most important prognostic factors: IGHV mutational 
status and fluorescence in situ hybridization (FISH) cytogenetics. Barcelona score identify 
three risk groups with different 10-year OS (Table III).
These novel prognostic factors aim at assisting patient management (i.e., define the fol-
low-up strategy based on the risk of developing progressive disease, especially for patients 
with low tumor burden at diagnosis) and treatment decision [7]. The presence of del(17p) and/
or mutated TP53 has in fact been associated with resistance to standard chemotherapy regi-
stage Description
Rai [4,5]
0 (low risk risk) Lymphocytosis in the peripheral blood and/or in the bone 
marrow.
I-II (intermediate 
risk)
Lymphocytosis in the peripheral blood + enlarged lymph 
nodes in any sites + splenomegaly and/or hepatomegaly.
III-IV (high risk) Lymphocytosis with disease-related anemia (Hb <11 g/
dL) or thrombocytopenia (platelets count <100×109/L).
Binet [6]
A Hb ≥10 g/dL + platelet count ≥100×109/L + <3 lymph 
node areas involved1.
B Hb ≥10 g/dL + platelet count ≥100×109/L + ≥3 lymph 
node areas involved1.
C Hb <10 g/dL and/or platelet count <100×109/L.
Table i. Staging systems [4-6]
1 Presence of enlarged lymph nodes ≥1 cm in diameter or organomegaly. Areas of 
involvement considered are head and neck (including the Waldeyer ring), axillae, groin, 
liver, and spleen
Prognostic factors 10-year Os
Del(17p) vs non del(17p) -87%
Serum β2-microglobulin concentration >3.5 mg/L vs ≤3.5 mg/L -73%
Unmutated vs mutated IGHV -68%
Mutated vs unmutated TP53 -55%
Binet stage B vs A -56.8%
Binet stage C vs A -46.4%
Age >65 vs ≤65 years -39%
Table ii. Impact of the independent factors identified by the CLL-IPI. Elaboration 
from [12]
Risk group Prognostic factors 10-year Os
Low Mutated IGHV and no del(17p)/del(11p) 82%
Intermediate Unmutated IGHV or del(17p)/del(11p) 52%
High Unmutated IGHV and del(17p)/del(11p) 27%
Table iii. Risk groups identified by the Barcelona score [13]
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mens (i.e., alkylating drugs and/or purine analogs) and poor response to chemoimmunother-
apy [10], while better outcomes have been achieved with novel inhibitors [10]. Similarly, the 
presence of mutated IGHV genes identify patients who have long-term disease free-survival 
after the treatment with fludarabine, cyclophosphamide, and rituximab (FCR) [14], while in 
patients with the unmutated IGHV pattern the treatment with the novel BTK inhibitor ibru-
tinib is associated with better outcomes when compared with chlorambucil (CHL) [15-17].
Recently published international guidelines and expert recommendations [10,11,18-21] 
have already recognized the usefulness of the new diagnostic and prognostic factors in the 
management of patients with CLL.
aim
Aim of this paper is to describe a real-life diagnostic and therapeutic approach to CLL 
proposed by an Italian Expert Panel with the objective to update the current patient manage-
ment in light of recent advances that have improved understanding of CLL. This new proposal 
has been developed and validated by ten key opinion leaders from Tuscany Region during 
two Expert Meetings. The approach suggested comes from their experience in daily clinical 
practice and is supported by guidelines recommendations, clinical trials results, and drugs 
prescribing conditions in Italy.
diagnosis of cLL
Onset of CLL is usually asymptomatic and the disease is discovered incidentally after a 
blood count evaluation performed for another reason. To differentiate CLL from MBL (mono-
clonal B-cell lymphocytosis), the diagnosis of CLL requires the presence, for at least three 
months, of ≥5×109/L monoclonal B cell lymphocytes in the peripheral blood [10,11]. The 
clonality of B-cells must be confirmed by flow cytometry in order to detect the CLL peculiar 
immunophenotypic profile: clonal kappa or lambda light chain restriction, co-expression of 
the surface antigen CD5 and the B-cell antigens CD19, CD20, and CD23, high expression of 
CD200 [22] and low levels of surface immunoglobulin CD20 and CD79b [10,11].
Table IV reports the examinations recommended to confirm the diagnosis of CLL and 
predict patient prognosis [10,11].
In particular, molecular analysis to detect IGHV mutation status can provide useful prog-
nostic information, especially in patients with low tumor burden at diagnosis, and enable 
physicians to provide more accurate patient counseling and define the frequency of follow-up. 
Furthermore, IGHV mutation status remains unchanged over time; thus it can inform therapy 
selection before starting treatment [7,10-13,23,24].
Time Examinations recommended
At diagnosis  • Detailed anamnesis with particular attention to prior or current malignancy.
 • Blood tests: CBC, LDH, creatinine, total protein levels, serum protein electrophoresis, transaminases, bilirubin, 
β2-microglobulin, IgG, IgA, and IgM levels.
 • Microscopic examination of the peripheral blood smear.
 • Immunophenotype: flow cytometry on peripheral blood lymphocytes.
 • Physical examination (abdomen and palpable lymph nodes).
 • Imaging: ultrasound and X-ray of chest.
 • Molecular analysis: IGHV mutation status (Sanger or NGS).
At follow-up 
(asymptomatic 
patients)
 • Blood tests: CBC, LDH, creatinine, total protein levels, serum protein electrophoresis, transaminases, bilirubin, 
b2-microglobulin, IgG, IgA, and IgM levels.
 • Physical examination (abdomen and palpable lymph nodes).
 • Imaging: abdomen ultrasound at least 1 time every 12 months1.
Before 
treatment
 • Detailed anamnesis with particular attention to polypharmacy e comorbility index (CIRS, ECOG, and Charlson).
 • Blood tests: as at diagnosis + QuantiFERON, infectious disease status (HBV, HCV, HIV; if IgG < 500 mg/dl 
detection/quantification of viral genomes).
 • Cytogenetic analysis: FISH on peripheral blood lymphocytes for chromosomes 11, 12, 13, and 17; conventional 
karyotyping of stimulated peripheral blood lymphocytes (aCGH).
 • Molecular analysis: IGHV mutation status (if not performed at diagnosis), TP53 mutation status (Sanger or NGS, 
cut off > 10%).
 • Heart tests: ECG, ECOCG.
Table iV. Examinations recommended at diagnosis, follow-up, and before treatment
1 Timing to be defined according to clinical need
aCGH = array-based Comparative Genomic Hybridization; CBC = complete blood count; CIRS = Cumulative Illness Rating Scale; ECG = 
electrocardiogram; ECOCG = echocardiogram; ECOG = Eastern Cooperative Oncology Group; FISH = Fluorescence in situ hybridization; IGHV = 
Immunoglobulin Heavy Chain Variable Region; LDL = low-density lipoprotein; NGS = next generation sequencing
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monitoring
According to IwCLL guidelines, pa-
tients with asymptomatic early-stage disease 
should be observed without therapy until 
disease progression or evidence of disease-
related symptoms [10].
A “watch and wait” strategy until evi-
dence of active disease is usually recom-
mended also in patients with intermediate 
and high-risk disease.
As reported in Figure 1, asymptomatic 
patients with early-stage disease should be 
followed-up 6 months after diagnosis in or-
der to exclude a rapid disease progression. 
Afterwards, in case of stable disease, follow-up may take place every 6-12 months. The ex-
aminations recommended at each follow-up visit are reported in Table IV.
treatment
Assessment before treatment
Table IV reports examinations recommended before treatment. In particular, cytoge-
netic analysis for the detection of del(11q) [10,11,13], trisomy 12 [10,11], del(13q) [10,11], 
del(17p) [10,11], conventional karyotyping of stimulated CLL cells [11,25], TP53 sequenc-
ing, and molecular genetic analysis to detect IGHV mutation status can provide useful prog-
nostic information and may guide selection of therapy [10,11].
Since cytogenetic abnormalities can evolve over time, re-evaluation of FISH, stimulated 
karyotype, and of TP53 mutational status are recommended before each subsequent line of 
treatment.
Furthermore, the choice of treatment should take into account age, comorbilities, perfor-
mance status, and creatinine clearance.
indication for treatment
As reported above, treatment should only be started in patients with progressive or symp-
tomatic disease (active disease) [10]. Active disease is defined by the presence of at least one 
of the criteria reported in Table V.
Neither the presence of del(17p), TP53 mutation, or other markers associated with poor 
prognosis, nor the absolute lymphocyte count, nor lymph node size, without the above men-
tioned criteria, should be used as indicator for treatment.
Assessment of response to treatment
In the recent years, the components of the panel acquired a huge experience about the 
employ of the ultrasound as fundamental tool for the response assessment. Indeed, according 
to the international guidelines, the quality of response is based on the disappearance/reduc-
Figure 1. Monitoring of patients without active disease
Criteria for initiating treatment  
(at least 1 of the following should be met)
 • Progressive lymphocytosis with an increase of ≥50% over 2 months or LDT <6 months (if lymphocytosis >30×109/L, a longer 
observation period may be required in patients with lymphocytosis <30×109/L).
 • Evidence of progressive marrow failure with development (or worsening) of anemia (Hb <10 g/dL) and/or thrombocytopenia 
(platelet count <100×109/L).
 • Massive (≥6 cm from the costal arch) or progressive or symptomatic splenomegaly.
 • Massive (nodes with longest diameter ≥10 cm) or progressive or symptomatic lymphadenopathy.
 • Autoimmune anemia and/or thrombocytopenia resistant to corticosteroids.
 • Symptomatic of functional extranodal involvement.
 • Disease-related systemic symptoms:
 • Weight loss ≥10% in the last 6 months
 • Significant asthenia/fatigue (ECOG ≥2)
 • Fever ≥38°C for ≥15 days without evidence of infection
 • Night sweats for ≥1 months without evidence of infection
Table V. Criteria that define active disease [10]
LDT = Lymphocyte Doubling Time
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tion or stability of the lymph nodes and spleen dimensions, assessed by CT scan and physical 
examination or by the physical examination only (in the general practice) [10]. In the routine, 
the physical examination is always subjective, with a high inter-individual variability, and CT 
scan exposes patient to a biological damage. On the contrary, the ultrasonography is a “bio-
logically safe” technique, with lower variability of interpretation, able to measure with preci-
sion the lymph nodes and spleen dimensions and to distinguish the “reactive” from the “still 
pathological” masses. In conclusion, the experts suggest adding the ultrasound assessment to 
the physical examination in the clinical daily practice.
i line treatment algorithm
Figure 2 reports the treatment algorithm proposed by the Expert Panel for the treatment 
of patients with CLL.
The most important characteristics that guide the choice of therapy are the presence of 
del(17p) and/or mutated TP53, IGHV mutational status, the presence of del(11q), age, and 
comorbidities.
Patients with TP53 mutation and/or del(17p)
Since chemoimmunotherapy showed poor outcome, patients with del(17p) and/or TP53 
mutation should be treated with novel inhibitors.
In particular, in the absence of contraindication, ibrutinib, an inhibitor of Bruton’s tyrosine 
kinase (BTK), is the preferred treatment option [11,26].
Adult patients who are not eligible for chemoimmunotherapy could be considered for 
therapy with idelalisib (an inhibitor of phosphatidylinositol 3-kinase p110δ), in combination 
with rituximab [27]; while patients who are unsuitable for B-cell receptor pathway inhibitors, 
could be considered for therapy with venetoclax (a BCL2 inhibitor) [28].
Patients without TP53 mutation or del(17p)
In these patients, IGHV mutational status and age are the main drivers to define treatment 
strategy.
Age ≥65 years
Unmutated IGHV. In the RESONATE-2 study [15-17], ibrutinib showed significantly 
higher overall response rate (ORR) and longer PFS compared to CHL and thus it is now the 
first choice of treatment. For patients who are not eligible to receive ibrutinib (in patients 
<70 years ibrutinib is indicated if at least one of the following criteria are satisfied: creatinine 
clearance <70 mL/min, ECOG 1-2, anemia <10 g/dL or thrombocytopenia <100.000/µL [29]) 
the second choice of treatment is the combination of the new anti-CD20 monoclonal antibody 
obinutuzumab and chlorambucil (G-CHL).
Mutated IGHV. As reported above, ibrutinib is associated with better outcomes com-
pared to CHL [15-17]. Furthermore, the Alliance North American Intergroup Study showed 
Figure 2. Treatment algorithm for patients with CLL
1 In patients <70 years ibrutinib is indicated if at least one of the following criteria are satisfied: creatinine clearance <70 mL/min, ECOG 1-2, anemia <10 
g/dL or thrombocytopenia <100.000/µL [29]; 2 Evaluated at the discretion of the clinician
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that, among older patients (≥65 years), treat-
ment with ibrutinib was superior to the com-
bination of rituximab and bendamustine (R-
bendamustine) in terms of PFS [30].
Although OS was not statistically differ-
ent, chemoimmunotherapy could still be a 
good option for these patients, when deletion 
of chromosome 11 has been excluded. The 
regimens more frequently adopted by the ex-
perts resulted: R-bendamustine, low-dose of 
FCR [31] and G-chlorambucil.
Age <65 years
Unmutated IGHV. Recent studies high-
lighted the limits of treatment with FCR in 
young unmutated IGHV patients in favor of 
ibrutinib [32]. Waiting for the approval of ibrutinib for this indication, chemoimmunotherapy 
with FCR remains the standard of care in these patients [11,14,33]. Patients who complete 6 
cycles of FCR achieve better outcomes [14]; however, based on our clinical experience, we 
recommend assessing the response already after 3 cycles. In case of complete response (CR), 
we suggest continuing with FCR regimen for other 3 cycles, otherwise, in case of sub-optimal 
response (evaluated at the discretion of the clinician), it is recommended to discontinue FCR 
treatment and move to the II line treatment.
Mutated IGHV. In these patients, the treatments recommended are FCR and R-benda-
mustine. FCR is associated with better outcomes, while R-bendamustine is associated with 
less toxic effects [34]; therefore, the choice of type and duration of treatment should be made 
at the discretion of the clinician.
Relapsed therapy
According to IwCLL guidelines relapse is defined as «evidence of disease progression in 
a patient who has previously achieved the above criteria of complete or partial remission for 
≥6 months» [10].
Figure 3 reports the recommended relapsed therapies.
concLusions
The Expert Panel, consisting of clinicians with experience in management of CLL, recog-
nized the limitations associated with traditional staging systems in identifying patients who 
will have a more aggressive disease course and predicting response to treatment.
Therefore, based on their clinical practice, guidelines recommendations, clinical trials re-
sults, and drugs prescribing conditions, they suggested a new diagnostic and therapeutic ap-
proach that takes into account the role of genomic and somatic prognostic factors in the risk 
stratification of developing progressive disease, and treatment decision. In particular, beside 
TP53 deletion or mutated status, they highlighted the importance of the IGHV mutation sta-
tus characterization, since the diagnosis, in order to identify patients who will have a more 
aggressive progression. Furthermore, just before starting treatment, to obtain useful prognos-
tic information and indication in the selection of the therapy, they agreed with other groups 
and guidelines to recommend cytogenetic analysis for the detection of del(11q), trisomy 12, 
del(13q), del(17p), conventional karyotyping of stimulated CLL cells, TP53 sequencing, and 
molecular genetic analysis to detect IGHV mutation status.
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Figure 3. Relapsed therapy
1 The use of R-venetoclax will be considered after the publication of reimbursement criteria 
in the Italian Official Gazette
2 Re-treatment with R-bendamustine should be considered after at least 36 months from 
relapse only in patients with unmutated TP53 and mutated IGHV status
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